Sen. Chuck Grassley (R-IA) with Sens. Marsha Blackburn (R-TN) and Ron Johnson (R-WI) (Graeme Sloan/Sipa USA/Sipa via AP Images)
October 17, 2022 03:25 PM EDT
FDA+
Law

Sen­a­tors call on NIH to take ac­tion on slow-to-re­port clin­i­cal tri­al spon­sors

Zachary Brennan

Senior Editor

With tens of bil­lions in an­nu­al ap­pro­pri­a­tions, a group of four Re­pub­li­can sen­a­tors is pub­licly won­der­ing why the Na­tion­al In­sti­tutes of Health can’t do a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

White House threat­ens ‘most fa­vored na­tion’ plan to low­er US drug prices, but many ques­tions re­main

Trump says he'll sign or­der on 'most fa­vored na­tion' drug price plans Mon­day

Lil­ly says fur­ther head-to-head tri­al da­ta back Zep­bound over No­vo’s We­govy

Lil­ly shuf­fles key ex­ec­u­tive po­si­tions; Mikael Dol­sten takes an­oth­er post-Pfiz­er as­sign­ment

From deal to dis­as­ter: Drug­mak­ers face a changed Wash­ing­ton as Trump em­braces ‘most fa­vored na­tion’ prices

Rev­o­lu­tion’s KRAS drugs ap­pear com­pet­i­tive in sev­er­al lung can­cer set­tings

A service from the Financial Times